Pomalidomide-amido-C3-COOH is primarily utilized in the development of targeted cancer therapies, particularly in the design of proteolysis-targeting chimeras (PROTACs). These molecules are engineered to degrade specific proteins involved in cancer progression by recruiting E3 ubiquitin ligases, leading to the ubiquitination and subsequent degradation of the target protein. Its structure allows for effective conjugation to ligands that bind to disease-relevant proteins, making it a valuable component in the creation of novel therapeutic agents. Additionally, it is explored in the modification of drug delivery systems to enhance the specificity and efficacy of anticancer drugs, reducing off-target effects and improving patient outcomes.